Back to search

McMaster University

Public Preferences for Financing Disease-Modifying Alzheimer’s Therapies: Elicitation, Aggregation, and the Credibility of Beliefs

Abstract

dc:description.abstract

Disease-modifying monoclonal antibodies for Alzheimer's disease, including lecanemab and donanemab, are under reimbursement review in Canada, raising financing decisions that cost-effectiveness analysis alone cannot resolve. This thesis examines public preferences for financing such therapies through three self-contained papers drawn from a single population-weighted survey of Ontario adults. The first paper measures what the public will collectively finance and how it believes the burden should be shared. Among 939 respondents, the population-weighted median voluntary contribution was $100 per year (95% CI $50–$100), and respondent-supported, majority-consistent revenue (approximately $1.16 billion under a uniform willingness-to-contribute schedule and $0.86 billion under a fairness-consistent schedule) exceeded projected per-adult program costs in every scenario examined; fair-tax allocations rose roughly twenty-fold across income brackets, indicating a systematic but bounded taste for progressivity. The second paper examines the structure beneath this aggregate. A latent class choice model of a private-financing discrete choice experiment recovers a two-class solution — a standard-trading majority (~89%) and a smaller minority (~11%) whose choices depart from standard demand patterns — and shows that willingness to pay is financing-contingent, so a single population estimate is an incomplete guide to policy. Class interpretation is disciplined using posterior inference of attitude–class relationships. The third paper interrogates the beliefs on which these valuations rest. Applying a probing elicitation framework (Giustinelli, Manski, and Molinari, 2022) to expectations about survival and Alzheimer's onset (N = 973), it finds that imprecise, interval-valued beliefs are the modal response on every outcome (49–60%), and that numeracy systematically predicts both response type and interval width. Together the papers advance a methodological position: credible preference evidence for policy requires measuring not only what people prefer, but who prefers it and how firmly the underlying beliefs are held.

Degree

thesis:*
Department dc:contributor.department
Health Management
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • von Schlegell, Ahmad
Advisor dc:contributor.advisor
  • Longo, Christopher

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
McMaster University
Base URL
macsphere.mcmaster.ca/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

von Schlegell, Ahmad. Public Preferences for Financing Disease-Modifying Alzheimer’s Therapies: Elicitation, Aggregation, and the Credibility of Beliefs. 2026. https://hdl.handle.net/11375/33497